125 related articles for article (PubMed ID: 24528019)
1. Monitoring microRNAs using a molecular beacon in CD133+/ CD338+ human lung adenocarcinoma-initiating A549 cells.
Yao Q; Sun JG; Ma H; Zhang AM; Lin S; Zhu CH; Zhang T; Chen ZT
Asian Pac J Cancer Prev; 2014; 15(1):161-6. PubMed ID: 24528019
[TBL] [Abstract][Full Text] [Related]
2. Lack of prognostic significance of neuroendocrine differentiation and stem cell antigen co-expression in resected early-stage non-small cell lung cancer.
Gottschling S; Jensen K; Herth FJ; Thomas M; Schnabel PA; Herpel E
Anticancer Res; 2013 Mar; 33(3):981-90. PubMed ID: 23482770
[TBL] [Abstract][Full Text] [Related]
3. Novel molecular beacons to monitor microRNAs in non-small-cell lung cancer.
Yao Q; Zhang AM; Ma H; Lin S; Wang XX; Sun JG; Chen ZT
Mol Cell Probes; 2012 Oct; 26(5):182-7. PubMed ID: 22796123
[TBL] [Abstract][Full Text] [Related]
4. Aberrant microRNAs expression in CD133⁺/CD326⁺ human lung adenocarcinoma initiating cells from A549.
Lin S; Sun JG; Wu JB; Long HX; Zhu CH; Xiang T; Ma H; Zhao ZQ; Yao Q; Zhang AM; Zhu B; Chen ZT
Mol Cells; 2012 Mar; 33(3):277-83. PubMed ID: 22349807
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-183 promotes migration and invasion of CD133(+)/CD326(+) lung adenocarcinoma initiating cells via PTPN4 inhibition.
Zhu C; Deng X; Wu J; Zhang J; Yang H; Fu S; Zhang Y; Han Y; Zou Y; Chen Z; Lin S
Tumour Biol; 2016 Aug; 37(8):11289-97. PubMed ID: 26951513
[TBL] [Abstract][Full Text] [Related]
6. Small nucleolar RNA signatures of lung tumor-initiating cells.
Mannoor K; Shen J; Liao J; Liu Z; Jiang F
Mol Cancer; 2014 May; 13():104. PubMed ID: 24886050
[TBL] [Abstract][Full Text] [Related]
7. Identification of carcinogenic potential-associated molecular mechanisms in CD133(+) A549 cells based on microRNA profiles.
Chen QY; Jiao DM; Zhu Y; Hu H; Wang J; Tang X; Chen J; Yan L
Tumour Biol; 2016 Jan; 37(1):521-30. PubMed ID: 26227219
[TBL] [Abstract][Full Text] [Related]
8. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells.
Chen YC; Hsu HS; Chen YW; Tsai TH; How CK; Wang CY; Hung SC; Chang YL; Tsai ML; Lee YY; Ku HH; Chiou SH
PLoS One; 2008 Jul; 3(7):e2637. PubMed ID: 18612434
[TBL] [Abstract][Full Text] [Related]
9. Functional differences of miR-125b on the invasion of primary glioblastoma CD133-negative cells and CD133-positive cells.
Shi L; Wan Y; Sun G; Gu X; Qian C; Yan W; Zhang S; Pan T; Wang Z; You Y
Neuromolecular Med; 2012 Dec; 14(4):303-16. PubMed ID: 22711523
[TBL] [Abstract][Full Text] [Related]
10. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas.
Li F; Zeng H; Ying K
Med Oncol; 2011 Dec; 28(4):1458-62. PubMed ID: 20717756
[TBL] [Abstract][Full Text] [Related]
11. The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells.
Shi Y; Liu C; Liu X; Tang DG; Wang J
PLoS One; 2014; 9(3):e90022. PubMed ID: 24595209
[TBL] [Abstract][Full Text] [Related]
12. [Progress of cancer stem cells of solid tumor].
Ni XG; Zhao P
Ai Zheng; 2006 Jun; 25(6):775-8. PubMed ID: 16764780
[TBL] [Abstract][Full Text] [Related]
13. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
[TBL] [Abstract][Full Text] [Related]
14. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer.
Cui F; Wang J; Chen D; Chen YJ
Oncol Rep; 2011 Mar; 25(3):701-8. PubMed ID: 21174061
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of PROM1 (CD133) confers poor prognosis in non-small cell lung cancer.
Qiu ZX; Zhao S; Mo XM; Li WM
Int J Clin Exp Pathol; 2015; 8(6):6589-95. PubMed ID: 26261540
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-187-5p suppresses cancer cell progression in non-small cell lung cancer (NSCLC) through down-regulation of CYP1B1.
Mao M; Wu Z; Chen J
Biochem Biophys Res Commun; 2016 Sep; 478(2):649-55. PubMed ID: 27495872
[TBL] [Abstract][Full Text] [Related]
17. Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells.
Meng X; Li M; Wang X; Wang Y; Ma D
Cancer Sci; 2009 Jun; 100(6):1040-6. PubMed ID: 19385971
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.
Ma Y; Li X; Cheng S; Wei W; Li Y
Mol Med Rep; 2015 Jan; 11(1):625-32. PubMed ID: 25339370
[TBL] [Abstract][Full Text] [Related]
19. Detection of miR-155-5p and imaging lung cancer for early diagnosis: in vitro and in vivo study.
Zhu HZ; Fang CJ; Guo Y; Zhang Q; Huang LM; Qiu D; Chen GP; Pang XF; Hu JJ; Sun JG; Chen ZT
J Cancer Res Clin Oncol; 2020 Aug; 146(8):1941-1951. PubMed ID: 32447486
[TBL] [Abstract][Full Text] [Related]
20. Analysis of microRNA (miRNA) expression profiles reveals 11 key biomarkers associated with non-small cell lung cancer.
Wang K; Chen M; Wu W
World J Surg Oncol; 2017 Sep; 15(1):175. PubMed ID: 28927412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
